Evidence map›Paper›PMID 33882092›Full record

ArticlePloS one2021

Finding, treating and retaining persons with HIV in a high HIV prevalence and high treatment coverage country: Results from the Botswana Combination Prevention Project.

Pamela Bachanas, Mary Grace Alwano, Refeletswe Lebelonyane, Lisa Block, Stephanie Behel, Elliot Raizes, Gene Ussery, Huisheng Wang, Faith Ussery, Molly Pretorius Holme and 8 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01965470 (Botswana Combination Prevention Project), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01965470 phase4completednot on this map

Botswana Combination Prevention Project: -Evaluation Protocol (Protocol #1): Research Design and Impact Evaluation -Closed Clinical Cohort Protocol (Protocol #3) Implementation, Monitoring and Evaluation of Combination HIV Prevention Interventions in Rural and Peri-Urban Communities in Botswana

TypeinterventionalSponsorCenters for Disease Control and PreventionRan2013 to 2018ConditionsHIVArmsCombination Prevention, Enhanced Care
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 3 countries.

Pamela BachanasDivision of Global HIV/AIDS, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.ORCID 0000-0001-9408-9904
Mary Grace AlwanoDivision of Global HIV/AIDS, U.S. Centers for Disease Control and Prevention, Gaborone, Botswana.
Refeletswe LebelonyaneBotswana Ministry of Health and Wellness, Gaborone, Botswana.
Lisa BlockNorthrup Grumman, Atlanta, Georgia, United States of America.
Stephanie BehelDivision of Global HIV/AIDS, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Elliot RaizesDivision of Global HIV/AIDS, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Gene UsseryNorthrup Grumman, Atlanta, Georgia, United States of America.
Huisheng WangNorthrup Grumman, Atlanta, Georgia, United States of America.
Faith UsseryDivision of Global HIV/AIDS, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Molly Pretorius HolmeHarvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Connie SextonDivision of Global HIV/AIDS, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Sherri PalsDivision of Global HIV/AIDS, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Arielle LasryDivision of Global HIV/AIDS, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Lisetta Del CastilloDivision of Global HIV/AIDS, U.S. Centers for Disease Control and Prevention, Gaborone, Botswana.
Shannon HaderUNAIDS, Geneva, Switzerland.
Shahin LockmanHarvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Naomi BockDivision of Global HIV/AIDS, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Janet MooreDivision of Global HIV/AIDS, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Centers for Disease Control and Prevention · USNorthrop Grumman (United States) · USBrigham and Women's Hospital · USHarvard University · USJoint United Nations Programme on HIV/AIDS · CHMinistry of Health · BW

Funding

CGH CDC HHS U01 GH000447CGH CDC HHS U2G GH000073CGH CDC HHS U2G GH000419CGH CDC HHS U2G GH001911
6 · The paper itself

Abstract

introductionThe scale-up of Universal Test and Treat has resulted in reductions in HIV morbidity, mortality and incidence. However, healthcare system and personal challenges have impacted the levels of treatment coverage achieved. We implemented interventions to improve linkage to care, retention, viral load (VL) coverage and service delivery, and describe the HIV care cascade over the course of the Botswana Combination Prevention Project (BCPP) study.

methodsBCPP was designed to evaluate the impact of prevention interventions on HIV incidence in 30 communities in Botswana. We followed a longitudinal cohort of newly identified and known HIV-positive persons not on antiretroviral therapy (ART) identified through community-based testing activities through BCPP and referred with appointments to local HIV clinics in 15 intervention communities. Those who did not keep the first or follow-up appointments were tracked and traced through phone and home contacts. Improvements to service delivery models in the intervention clinics were also implemented.

resultsA total of 3,657 newly identified or HIV-positive persons not on ART were identified and referred to their local HIV clinic; 90% (3,282/3,657) linked to care and of those, 93% (3,066/3,282) initiated treatment. Near the end of the study, 221 persons remained >90 days late for appointments or missing. Tracing efforts identified 54/3,066 (2%) persons who initiated treatment but died, and 106/3,066 (3%) persons were located and returned to treatment. At study end, 61/3,066 (2%) persons remained missing and were never reached. Overall, 2,951 (98%) persons living with HIV (PLHIV) who initiated treatment were still alive, retained in care and still receiving ART out of the 3,001 persons alive at the end of the study. Of those on ART, 2,854 (97%) had current VL results and 2,784 (98%) of those were virally suppressed at study end.

conclusionsThis study achieved high rates of linkage, treatment initiation, retention and VL coverage and suppression in a cohort of newly identified and known PLHIV not on ART. Tracking and tracing interventions effectively identified those persons who needed more resource intensive follow-up. The interventions implemented to improve service delivery and data quality may have also contributed to high linkage and retention rates. Clinical trial number: NCT01965470.

Indexed as

AdolescentAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBotswanaDelivery of Health CareFemaleHIV InfectionsHumansIncidenceMaleMass ScreeningPrevalenceViral LoadYoung AdultAnti-HIV Agents

Identifiers

PMID33882092
PMCPMC8059857
OpenAlexW3152924523

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.